Prices are updated after-hours

Manufacturing 2021 - 05 - 13

KemPharm Inc

KMPH | $5.46 6.04% 0

|

(0.0% 1d) (0.7% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.7% 7d) (NaN% volume)
Earnings Calendar: 2023-03-30
Market Cap: $ 188,396,547
http://www.kempharm.com/
Sec Filling | Patents | 22 employees

(US) KemPharm is a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its proprietary LAT™ (Ligand Activated Therapy) technology. KemPharm utilizes its proprietary LAT™ technology to generate improved prodrug versions of FDA-approved drugs as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. KemPharm's prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, or ADHD, and stimulant use disorder. KemPharm's co-lead clinical development candidates for the treatment of ADHD, KP415 and KP484, are both based on a prodrug of d-methylphenidate, but have differing duration/effect profiles. In addition, KemPharm has received FDA approval for APADAZ®, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen.

urea treatment profitable

add to watch list Paper trade email alert is off

Arrival

ARVL | News | $0.49 0.37% 2.5M

|

(0.0% 1d) (0.0% 1m) (-83.6% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (NaN% volume)
Earnings Calendar: 2023-09-07
Market Cap: $ 373,986,571
https://arrival.com
Sec Filling | Patents | n/a employees

Arrival is reinventing the automotive industry with its entirely new approach to the design and assembly of electric vehicles. Low CapEx, rapidly scalable Microfactories combined with proprietary in-house developed components, materials and software, enable the production of best in class vehicles competitively priced to fossil fuel variants and with a substantially lower total cost of ownership. This transformative approach provides cities globally with the solutions they need to create sustainable urban environments and exceptional experiences for their citizens. Arrival is a global business founded in 2015 and headquartered in London, UK and Charlotte, North Carolina, USA, with more than 1800 global employees located in offices across the United States, Germany, the Netherlands, Israel, Russia, and Luxembourg. The company is deploying its first three microfactories in North Carolina, USA, South Carolina, USA and Bicester, UK in 2021.

electric vehicles solar automotive vehicles israel housing eletrical

add to watch list Paper trade email alert is off

Lightning eMotors Inc

ZEV | $1.63 0.0% 79K

|

(0.0% 1d) (0.0% 1m) (-74.4% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-1.0% volume)
Earnings Calendar: 2023-11-06
Market Cap: $ 10,533,733
https://lightningemotors.com/
Sec Filling | Patents | 2 employees

(United States) Lightning eMotors, Inc. operates as an automobile company. The Company manufactures electric fleet medium- and heavy-duty vehicles, including delivery trucks, shuttle buses, passenger vans, chassis-cab models, and city transit buses. Lightning eMotors serves customers worldwide.

eletrical vehicles

add to watch list Paper trade email alert is off

Greenbrook TMS Inc

GBNH | $0.121 -4.88% 6M

|

(0.0% 1d) (0.0% 1m) (-76.4% 1y) (-24.5% 2d) (-24.5% 3d) (0.0% 7d) (-100.0% volume)
Earnings Calendar:
Market Cap: $ 4,936,822
https://greenbrooktms.com
Sec Filling | Patents | n/a employees

Operating through 123 Company-operated treatment centers, Greenbrook is a leading provider of TMS therapy, an FDA-cleared,non-invasive therapy for the treatment of Major Depressive Disorder and other mental health disorders, in the United States. TMS therapy provides local electromagnetic stimulation to specific brain regions known to be directly associated with mood regulation. Greenbrook has provided more than 370,000 TMS treatments to close to 10,000 patients struggling with depression.

treatment

add to watch list Paper trade email alert is off

Edgewise Therapeutics Inc

EWTX | $15.23 -1.42% -1.44% 540K

|

(0.0% 1d) (-0.8% 1m) (138.9% 1y) (0.0% 2d) (0.0% 3d) (0.9% 7d) (39.07% volume)
Earnings Calendar: 2023-11-02
Market Cap: $ 1,418,074,788
https://edgewisetx.com
Sec Filling | Patents | n/a employees

Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders for which there is significant unmet medical need. Guided by its holistic drug discovery approach to targeting the muscle as an organ, Edgewise has combined its foundational expertise in muscle biology and small molecule engineering to build its proprietary, muscle focused drug discovery platform. Edgewise’s platform utilizes custom-built high throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue, initially focused on addressing rare neuromuscular and cardiac diseases.

drug discovery treatment

add to watch list Paper trade email alert is off

Cricut Inc - Class A

CRCT | $5.26 1.54% 1.52% 620K

|

(0.0% 1d) (-2.3% 1m) (-49.1% 1y) (0.0% 2d) (0.0% 3d) (-0.2% 7d) (-19.84% volume)
Earnings Calendar: 2024-03-05
Market Cap: $ 266,095,594
https://cricut.com
Sec Filling | Patents | n/a employees

Cricut Inc. is a creative technology platform company dedicated to encouraging new ways for people to experience making at home. As an empowering lifestyle brand, Cricut’s mission is to unleash the creative potential of its users with innovations that bring ideas to life in the form of professional-looking, personalized handmade projects. Cricut’s industry-leading products include its flagship line of smart cutting machines—Cricut Maker®, the Cricut Explore® family, and Cricut Joy®— accompanied by other unique tools like Cricut EasyPress®, the Infusible Ink™ system, and a diverse collection of materials. In addition to Cricut’s core offerings, the brand also fosters a thriving community of more than four million dedicated users worldwide.

brands

add to watch list Paper trade email alert is off

LifeMD Inc

LFMD | $9.7 -5.0% -5.26% 490K

|

(0.0% 1d) (-14.4% 1m) (460.8% 1y) (0.0% 2d) (0.0% 3d) (2.7% 7d) (14.48% volume)
Earnings Calendar:
Market Cap: $ 391,550,656
https://lifemd.com
Sec Filling | Patents | 56 employees

LifeMD, Inc. (formerly Conversion Labs) is a leading telehealth company that is transforming the healthcare landscape with direct-to-patient product and service offerings. LifeMD's telemedicine platform enables virtual access to affordable and convenient medical treatment from licensed providers and, when appropriate, prescription medications and over-the-counter products delivered directly to the patient's home.

treatment

add to watch list Paper trade email alert is off

Nuwellis Inc

NUWE | $0.255 -2.07% -2.12% 230K

|

(0.0% 1d) (-37.8% 1m) (-93.6% 1y) (0.0% 2d) (0.0% 3d) (-24.0% 7d) (431.14% volume)
Earnings Calendar: 2024-02-27
Market Cap: $ 1,734,368
https://www.nuwellis.com
Sec Filling | Patents | 15027 employees

(US) Nuwellis, Inc. , formally CHF Solutions, is a medical device company dedicated to changing the lives of patients suffering from fluid overload through science, collaboration, and innovation. The Company is focused on developing, manufacturing and commercializing the Aquadex SmartFlow® system for ultrafiltration therapy. Nuwellis is headquartered in Minneapolis, Minn., with a wholly-owned subsidiary in Ireland. The Company has been listed on the Nasdaq Capital Market since February 2012, previously branded as CHF Solutions

brands

add to watch list Paper trade email alert is off

Garrett Motion Inc - New

GTX | $9.36 1.08% 1.07% 800K

|

(0.0% 1d) (-6.4% 1m) (11.6% 1y) (0.0% 2d) (0.0% 3d) (-2.0% 7d) (-6.96% volume)
Earnings Calendar: 2024-02-15
Market Cap: $ 2,126,702,598
https://www.garrettmotion.com/
Sec Filling | Patents | 3 employees

(CH) Garrett Motion is a differentiated technology leader, serving customers worldwide for more than 65 years with passenger vehicle, commercial vehicle, aftermarket replacement and performance enhancement solutions. Garrett’s cutting-edge technology enables vehicles to become safer, more connected, efficient and environmentally friendly. The Company's portfolio of turbocharging, electric boosting and automotive software solutions empowers the transportation industry to redefine and further advance motion.

automotive eletrical vehicles

add to watch list Paper trade email alert is off

Movano Inc

MOVE | $0.484 -2.63% 26K

|

(0.0% 1d) (11.9% 1m) (-57.1% 1y) (0.0% 2d) (0.0% 3d) (-3.7% 7d) (-43.77% volume)
Earnings Calendar:
Market Cap: $ 47,540,933

Sec Filling | Patents | 15 employees

movano is a health-focused technology company that believes glucose is an important health metric to continuously track, as glucose levels serve as a proxy for metabolic health and risk for chronic disease, such as diabetes. we also believe that whether you are a person with diabetes, prediabetes or someone looking to pursue a healthier lifestyle, monitoring and managing your glucose levels shouldn’t be painful, complicated or conspicuous.

add to watch list Paper trade email alert is off

Ikena Oncology Inc

IKNA | $1.3 3.18% 3.08% 330K

|

(0.0% 1d) (-20.3% 1m) (-73.7% 1y) (0.0% 2d) (0.0% 3d) (-3.1% 7d) (-15.39% volume)
Earnings Calendar: 2023-11-06
Market Cap: $ 62,735,544
https://www.ikenaoncology.com
Sec Filling | Patents | 67 employees

Ikena Oncology is a targeted oncology company focused on developing cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. Ikena is advancing five programs that include four product candidates in either clinical development or IND-enabling studies: IK-930, a TEAD inhibitor targeting the Hippo signaling pathway; an ERK5 inhibitor program targeting the KRAS signaling pathway; IK-175, an AHR antagonist; IK-412, a kynurenine-degrading enzyme; and IK-007, an EP4 receptor antagonist. Ikena has entered into a global strategic collaboration with Bristol-Myers Squibb Company for its IK-175 and IK-412 programs.

cancer

add to watch list Paper trade email alert is off

Interlink Electronics

LINK | $6.57 -4.44% -4.64% 1.2K

|

(0.0% 1d) (-37.3% 1m) (-19.6% 1y) (0.0% 2d) (0.0% 3d) (3.8% 7d) (-88.74% volume)
Earnings Calendar:
Market Cap: $ 64,782,532
https://www.interlinkelectronics.com
Sec Filling | Patents | n/a employees

Interlink Electronics is a world-leading trusted provider of HMI, sensor, and IoT solutions. In addition to standard product offerings, Interlink utilizes its expertise in materials science, manufacturing, firmware, and software to produce in-house system solutions for custom applications. For 35 years, Interlink has led the printed electronics industry in the commercialization of its patented Force Sensing Resistor® technology and has supplied some of the world's top electronics manufacturers with intuitive sensor and interface technologies like the VersaPad and the new VersaPad Plus, which boasts the largest active surface area of any resistive touchpad. It also has a proven track record of supplying technological solutions for mission-critical applications in a diverse range of markets—including medical, automotive, consumer electronics, telecommunications, and industrial control—providing standard and custom-designed sensors that give engineers the flexibility and functionally they seek in today's sophisticated electronic devices. Interlink serves an international customer base from its headquarters in Irvine, Calif., and pending world-class materials science lab and R&D center in Camarillo, Calif. They are supported by strategic global locations covering manufacturing, distribution, and sales support.

automotive urea housing electronics sensor

add to watch list Paper trade email alert is off

Eledon Pharmaceuticals Inc

ELDN | $1.85 -7.03% -7.57% 420K

|

(0.0% 1d) (-5.3% 1m) (-35.5% 1y) (0.0% 2d) (0.0% 3d) (-2.4% 7d) (-75.9% volume)
Earnings Calendar: 2024-03-28
Market Cap: $ 45,904,291
http://novustherapeutics.com/
Sec Filling | Patents | 10 employees

(US) Novus Therapeutics, Inc. is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and for patients living with ALS. The company’s lead compound in development is AT-1501, a humanized IgG1 anti-CD40L antibody with high affinity for CD40 ligand (CD40L, also called CD154), a well-validated biological target with broad therapeutic potential. The CD40L/CD40 pathway is widely recognized for its prominent role in immune regulation. CD40L is primarily expressed on activated CD4+ T cells, platelets and endothelial cells while the CD40 receptor is constitutively expressed on antigen presenting cells such as B cells, macrophages, and dendritic cells. By blocking CD40L and not the CD40 receptor, AT-1501 inhibits both the CD40 and CD11 costimulatory signaling pathways, providing the potential for improved efficacy compared to anti-CD40 receptor approaches. Blocking CD40L also increases polarization of CD4+ lymphocytes to Tregs, a specialized subpopulation of T cells that act to suppress an immune response, thus creating a more tolerogenic environment, which is especially important for autoimmune diseases and in the transplant setting. Furthermore AT-1501 is an IgG1 antibody specifically engineered to cripple the Fc effector function to potentially improve safety, as well as potentially provide pharmacokinetic, pharmacodynamic, and dosing advantages compared to other approaches.

als ceiling treatment antibody t-cell

add to watch list Paper trade email alert is off

Asensus Surgical Inc

ASXC | $0.25 -1.07% 0.0% 1.1M

|

(0.0% 1d) (-9.4% 1m) (-65.2% 1y) (0.0% 2d) (0.0% 3d) (-5.1% 7d) (11.21% volume)
Earnings Calendar:
Market Cap: $ 67,996,592
https://asensus.com
Sec Filling | Patents | 133 employees

(United States) Asensus Surgical, Inc. is digitizing the interface between the surgeon and patient to pioneer a new era of Performance-Guided Surgery by unlocking the Clinical Intelligence to enable consistently superior outcomes and a new standard of surgery. This builds upon the foundation of Digital Laparoscopy with the Senhance® Surgical System powered by the Intelligent Surgical Unit™ (ISU™) to increase surgeon control and reduce surgical variability. With the addition of machine vision, augmented intelligence, and deep learning capabilities throughout the surgical experience, we intend to holistically address the current clinical, cognitive and economic shortcomings that drive surgical outcomes and value-based healthcare.

education

add to watch list Paper trade email alert is off

Flora Growth Corp

FLGC 4 | $1.56 -7.14% -7.69% 280K

|

(0.0% 1d) (40.9% 1m) (-60.2% 1y) (0.0% 2d) (0.0% 3d) (-1.1% 7d) (-34.21% volume)
Earnings Calendar: 2023-05-15
Market Cap: $ 16,668,344
https://floragrowth.ca
Sec Filling | Patents | 2021 employees

Flora is a cannabis company that leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its diverse business divisions of cosmetics, hemp textiles, and food and beverage. As the operator of one of the largest outdoor cultivation facilities, Flora strives to market a higher-quality premium product at below market prices. By prioritizing natural ingredients and value-chain sustainability across its portfolio, Flora creates premium products that help consumers restore and thrive.

add to watch list Paper trade email alert is off

Viracta Therapeutics Inc

VIRX | $0.88 -3.19% -3.3% 53K

|

(0.0% 1d) (-16.8% 1m) (-28.2% 1y) (0.0% 2d) (0.0% 3d) (20.5% 7d) (-23.43% volume)
Earnings Calendar: 2024-03-13
Market Cap: $ 34,559,742
http://www.sunesis.com/
Sec Filling | Patents | 8 employees

(US) Viracta is a precision oncology company targeting virus-associated malignancies. The Company's proprietary investigational drug, nanatinostat, is currently being evaluated in combination with the antiviral agent valganciclovir as an oral combination therapy in a Phase 2 clinical trial for EBV-positive lymphomas. Viracta is pursuing application of this inducible synthetic lethality approach in other EBV-associated malignancies, such as nasopharyngeal carcinoma, gastric carcinoma, and other virus-related cancers.

cancer antiviral

add to watch list Paper trade email alert is off

Cantaloupe Inc

CTLP | $6.16 -0.16% -0.16% 180K

|

(0.0% 1d) (-0.6% 1m) (14.3% 1y) (0.0% 2d) (0.0% 3d) (1.1% 7d) (-17.65% volume)
Earnings Calendar: 2024-02-08
Market Cap: $ 448,429,662
https://www.cantaloupesys.com
Sec Filling | Patents | 225 employees

(US) Cantaloupe, Inc. is a software and payments company that provides end-to-end technology solutions for the unattended retail market. USAT is transforming the unattended retail community by offering one integrated solution for payments processing, logistics, and back-office management. The Company’s enterprise-wide platform is designed to increase consumer engagement and sales revenue through digital payments, digital advertising and customer loyalty programs, while providing retailers with control and visibility over their operations and inventory. As a result, customers ranging from vending machine companies, to operators of micro-markets, gas and car charging stations, laundromats, metered parking terminals, kiosks, amusements and more, can run their businesses more proactively, predictably, and competitively.

msa digital advertising payment

add to watch list Paper trade email alert is off

Your Today's Watch List

Sign in to create a watchlist

Gainers vs Losers

67%

33%

Top 10 Gainers

AGBA | News | $1.26 215.0% 68.25% 130M

|

EGOX | $0.0515 43.06% 30.1% 330M

|

OLB 4 | $0.33 -14.95% 25.53% 840K

|

Technology Services

NVFY | $2.77 31.28% 23.83% 33M

|

Consumer Durables

ZCMD | $1.87 28.97% 22.46% 31M

|

Commercial Services

RCON | $0.1112 13.01% 21.28% 1.7M

|

Distribution Services

INSG | $3.03 25.21% 20.13% 330K

|

Electronic Technology

GCTK | $0.8191 22.25% 18.2% 190K

|

WLGS | News | $0.59 18.0% 17.9% 2.3M

|

ASNS | $0.828 21.75% 17.86% 18K

|

Last 48 Hours Insiders Buying

CLSD | $1.29 -2.27% -2.33% 230K

|

Health Technology

| 14:00
CDZI P 25000 | $2.25 0.0% 260K

|

| 14:00
ETST P 39000 | $0.068 -67.14% 43K

|

| 13:30
FNLC P 1275 | $22.97 3.66% 3.53% 21K

|

| 12:30
ADMQ | $0.0532 -40.18% 480K

|

| 10:30
AXR P 2400 | $21.0 -5.28% 0.0% 13K

|

| 21:00
QCRH P 118 | $57.315 3.44% 3.32% 66K

|

| 18:01
VUZI P 7500 | $1.19 -5.56% -5.88% 550K

|

Electronic Technology

| 18:00
RMCF | $3.67 3.38% 3.27% 11K

|

Consumer Non-Durables

| 20:10

12 months watchlist earnings calendar